{"url_path":"/sec/plyx/8-k/2026-07-21/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-080041-index.html","accession_number":"0001213900-26-080041","cik":"0002075320","ticker":"PLYX","issuer_name":"Polaryx Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-080041-index.html","primary_entity_key":"0002075320","primary_entity_name":"Polaryx Therapeutics, Inc."},"word_count":142,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n** **\n\nOn July 19, 2026,\nLisa Bollinger, MD, Chief Medical Officer of Polaryx Therapeutics, Inc. (the “Company”), resigned from her position with\nthe Company, effective immediately. The Company does not anticipate that Dr. Bollinger’s resignation will affect previously\ndisclosed clinical timelines, regulatory plans or development strategy.\n\n \n\nThe Company has commenced a search for a successor. In the\ninterim, responsibilities previously overseen by Dr. Bollinger will be assumed by members of the Company’s existing leadership\nteam.\n\n \n\n 1 \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto\nduly authorized.\n\n \n\n \n**Polaryx Therapeutics, Inc.**\n\n \n \n\n \n*/s/ Alex Yang*\n\n \nAlex Yang\n\n \nChief Executive Officer\n\n \n \n\nDate: July 21, 2026\n\n \n\n \n\n 2"}